Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
5 October 2021

Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer

Authors: Firas Baidoun https://orcid.org/0000-0003-3584-9453 [email protected], Anas M Saad, and Omar Abdel-Rahman https://orcid.org/0000-0002-5117-2502Author Info & Affiliations
Volume 10, Number 16
https://doi.org/10.2217/cer-2021-0013
PDFFormats

Abstract

Objectives: Compare overall survival (OS) between microsatellite instability (MSI) high and MSI-stable and analyze the effect of chemotherapy on OS. Methods: National cancer database was queried for patients diagnosed with colorectal adenocarcinoma between 2010 and 2016. We evaluated the OS and the chemotherapy effect using Kaplan–Meier estimates and multivariate Cox regression analyses. Results: Total of 30,436 stage II patients and 30,302 stage III patients were included. In stage II with high-risk features and MSI-high, patients who received chemotherapy had better OS compared to patients who didn't receive chemotherapy. The same was found in stage II with no high-risk features and MSI-high group. Conclusion: Stage II colorectal cancer patients with high-risk features and MSI-high who received chemotherapy have better OS compared to patients who didn't receive chemotherapy.

Supplementary Material

File (suppl_file.zip)
File (supplementary figure 1.docx)
File (supplementary figure 2.docx)
File (supplementary figure 3.docx)
File (supplementary figure 4.docx)
File (supplementary figure 5.docx)
File (supplementary figure a.docx)
File (supplementary figure b.docx)
File (supplementary figure c.docx)
File (supplementary figure d.docx)
File (supplementary table a.docx)
File (supplementary table b.docx)
File (supplementary table c.docx)
File (supplementary table d.docx)

References

Papers of special note have been highlighted as: • of interest
1.
National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program cancer stat facts: colorectal cancer (2021). https://seer.cancer.gov/statfacts/html/colorect.html
Google Scholar
2.
American Cancer Society. Key statistics for colorectal cancer (2021). www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
Google Scholar
3.
Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70(3), 145–164 (2020).
PubMed
Google Scholar
4.
Kikuchi T, Mimura K, Okayama H et al. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol. Lett. 18(6), 5977–5985 (2019).
PubMed
Google Scholar
5.
Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 5(1), 16–18 (2015).
PubMed
Google Scholar
6.
Kawakami H, Zaanan A, Sinicrope FA. Microsatellite Instability Testing and its role in the management of colorectal cancer. Curr. Treat. Options Oncol. 16(7), 30 (2015).
PubMed
Google Scholar
7.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 138(6), 2073–2087.e3 (2010).
PubMed
Google Scholar
8.
Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat. Rev. Clin. Oncol. 7(3), 174–177 (2010).
PubMed
Google Scholar
9.
Lamberti C, Lundin S, Bogdanow M et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal Dis. 22(2), 145–152 (2007).
PubMed
Google Scholar
10.
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609–618 (2005).
PubMed
Google Scholar
• Evaluates the effect of chemotherapy on overall survival in microsatellite instability high (MSI-H) colorectal cancer (CRC) patients.
11.
Andreotti G, Chen J, Gao YT et al. Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population-based study in China. Int. J. Cancer. 122(10), 2322–2329 (2008).
PubMed
Google Scholar
12.
National Cancer Database. About the National Cancer Database (2020). www.facs.org/quality-programs/cancer/ncdb/about
Google Scholar
13.
Argilés G, Tabernero J, Labianca R et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(10), 1291–1305 (2020).
PubMed
Google Scholar
14.
NCCN Clinical Practice Guidelines in Oncology –Colon Cancer (2021). www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Google Scholar
15.
Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Futur. Oncol. 7(3), 467–474 (2011).
PubMed
Google Scholar
16.
Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. Clin. Dev. Immunol. 2010, 1–13 (2010).
Google Scholar
17.
Dolcetti R, Guidoboni M, Viel A, Boiocchi M. Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10: 917–923, 2001. Cancer Epidemiol. Biomarkers Prev. 11(5), 499 (2002).
PubMed
Google Scholar
18.
Guidoboni M, Gafà R, Viel A et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am. J. Pathol. 159(1), 297–304 (2001).
PubMed
Google Scholar
19.
Sinicrope FA, Rego RL, Garrity-Park MM et al. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int. J. Cancer 120(6), 1232–1238 (2007).
PubMed
Google Scholar
• Discusses the mechanism of how MSI status affects the colon cancer tumor behavior.
20.
Benatti P, Gafà R, Barana D et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 11(23), 8332–8340 (2005).
PubMed
Google Scholar
21.
Carethers JM, Chauhan DP, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1), 123–131 (1999).
PubMed
Google Scholar
22.
Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56(21), 4881–6 (1996).
PubMed
Google Scholar
23.
Hawn MT, Umar A, Carethers JM et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55(17), 3721–5 (1995).
PubMed
Google Scholar
24.
Nehmé A, Baskaran R, Aebi S et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res. 57(15), 3253–7 (1997).
PubMed
Google Scholar
25.
Kim JE, Hong YS, Kim HJ et al. Defective mismatch repair status was not associated with DFS and OS in Stage II colon cancer treated with adjuvant chemotherapy. Ann. Surg. Oncol. 22, 630–637 (2015).
PubMed
Google Scholar
26.
Jover R. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55(6), 848–855 (2006).
PubMed
Google Scholar
27.
Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219–3226 (2010).
PubMed
Google Scholar
28.
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217), 1745–1750 (2000).
PubMed
Google Scholar
29.
Watanabe T, Wu T-T, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344(16), 1196–1206 (2001).
PubMed
Google Scholar
30.
Sargent DJ, Shi Q, Yothers G et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J. Clin. Oncol. 32(Suppl. 15), 3507–3507 (2014).
Google Scholar
31.
Mauri D, Zarkavelis G, Filis P et al. Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. ESMO Open 3(4), e000343 (2018).
PubMed
Google Scholar
32.
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer. 45(10), 1890–1896 (2009).
PubMed
Google Scholar
33.
Kim ST, Lee J, Park SH et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother. Pharmacol. 66(4), 659–667 (2010).
PubMed
Google Scholar
|